hpparα

Muraglitazar (BMS-298585) is a dual agonist of PPARα/γ that exerts metabolic regulatory effects including lipid modulation, glucose reduction, improvement of insulin resistance, and weight loss. It is indicated for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar exhibits potent in vitro activity against human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM).

NXT629 is a selective and highly efficient PPAR-α antagonist with anticancer activity. It inhibits PPARδ, PPARγ, Erβ, GR, and TRβ and can be used in research on ovarian cancer and melanoma.

sEH/PPARδ modulator 1 is a dual regulator of sEH and PPARδ. It inhibits sEH with an IC50 of 0.46 μM and activates PPARδ with an EC50 of 0.12 μM. This compound is applicable in research related to inflammation, metabolic disorders, and cardiovascular diseases.

GW 501516 (Endurobol) is a effective and highly specifc PPARβ/δ agonist (EC50: 1 nM), with 1000-fold selectivity over hPPARα/γ.

LT175, a dual PPARα/γ ligand, demonstrates potent insulin-sensitizing effects with reduced adipogenic properties. This orally active partial agonist targets PPARγ with EC50 values of 0.22 μm for hPPARα, 0.26 μm for mPPARα, and 0.48 μm for hPPARγ. LT175 specifically interacts with PPARγ, influencing the recruitment of coregulators, such as the cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1), within a hydrophobic region known as the diphenyl pocket [1].

GW 501516 (Standard) is the standard substance of GW 501516, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. GW 501516 (Endurobol) is a effective and highly specifc PPARβ/δ agonist (EC50: 1 nM), with 1000-fold selectivity over hPPARα/γ.